NO20051694L - Heterosykliske forbindelser - Google Patents

Heterosykliske forbindelser

Info

Publication number
NO20051694L
NO20051694L NO20051694A NO20051694A NO20051694L NO 20051694 L NO20051694 L NO 20051694L NO 20051694 A NO20051694 A NO 20051694A NO 20051694 A NO20051694 A NO 20051694A NO 20051694 L NO20051694 L NO 20051694L
Authority
NO
Norway
Prior art keywords
heterocyclic compounds
alkyl
benzoinidazol
nethanone
histamine
Prior art date
Application number
NO20051694A
Other languages
English (en)
Norwegian (no)
Inventor
James P Edwards
Nicholas I Carruthers
Curt A Dvorak
Cheryl A Grice
Jill A Jablonowski
Kiev S Ly
Barbara A Pio
Chandravadan Shah
Jennifer D Venable
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20051694L publication Critical patent/NO20051694L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20051694A 2002-09-06 2005-04-05 Heterosykliske forbindelser NO20051694L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40856902P 2002-09-06 2002-09-06
PCT/US2003/027461 WO2004022060A2 (en) 2002-09-06 2003-09-04 (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders

Publications (1)

Publication Number Publication Date
NO20051694L true NO20051694L (no) 2005-04-05

Family

ID=31978632

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051694A NO20051694L (no) 2002-09-06 2005-04-05 Heterosykliske forbindelser

Country Status (20)

Country Link
US (1) US7504426B2 (ja)
EP (1) EP1545532A2 (ja)
JP (1) JP2006500390A (ja)
KR (1) KR20050033662A (ja)
CN (1) CN1694704A (ja)
AR (1) AR041170A1 (ja)
AU (1) AU2003265886A1 (ja)
BR (1) BR0314059A (ja)
CA (1) CA2497827A1 (ja)
EC (1) ECSP055647A (ja)
IS (1) IS7716A (ja)
MX (1) MXPA05002575A (ja)
NO (1) NO20051694L (ja)
NZ (1) NZ538401A (ja)
PL (1) PL377087A1 (ja)
RS (1) RS20050201A (ja)
RU (1) RU2005106274A (ja)
UA (1) UA79309C2 (ja)
WO (1) WO2004022060A2 (ja)
ZA (1) ZA200502750B (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
IL163995A0 (en) * 2002-03-13 2005-12-18 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1545596A4 (en) * 2002-09-06 2005-12-28 Janssen Pharmaceutica Nv USE OF HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ALLERGIES AND ASTHMA
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479676A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Benzimidazole-derivatives as factor xa inhibitors
WO2005031308A2 (en) * 2003-09-26 2005-04-07 Janssen Pharmaceutica N.V. Analyzing histamine h4 receptor-mediated effects in whole blood
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
JP2008520644A (ja) * 2004-11-24 2008-06-19 ファイザー・インク オクタヒドロピロロ［３，４−ｃ］ピロール誘導体
ES2348829T3 (es) 2006-03-31 2010-12-15 Janssen Pharmaceutica Nv Benzimidazol-2-il-pirimidinas y pirazinas moduladoras del receptor h4 de histamina.
EP2010172B1 (en) * 2006-04-07 2012-08-29 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
US20090069343A1 (en) * 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
CA2674237C (en) 2006-12-28 2015-11-24 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CA2727627C (en) * 2008-06-12 2018-02-13 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
WO2011013752A1 (ja) * 2009-07-31 2011-02-03 塩野義製薬株式会社 縮合へテロ環誘導体を含有する医薬組成物
CN102656151A (zh) * 2009-09-04 2012-09-05 扎里卡斯药品有限公司 治疗疼痛和癫痫的取代的杂环衍生物
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
SI2611444T1 (sl) 2010-09-02 2016-04-29 Suven Life Sciences Limited Serene Chambers Spojine heterociklila kot ligandi receptorja histamina H3
US8859550B2 (en) 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用
CA2857344C (en) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EP3378476A1 (en) 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus
NZ743499A (en) 2012-08-28 2019-09-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
EA027194B1 (ru) 2013-02-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
BR112015021463A8 (pt) 2013-03-06 2019-11-19 Janssen Pharmaceutica Nv moduladores de benzoimidazol-2-il pirimidina do receptor histamínico h4,seu uso e composição faramacêutica
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
TR201807090T4 (tr) 2013-07-25 2018-06-21 Janssen Sciences Ireland Uc Glioksamid sübstitüeli pirrolamid deriveleri ve bunun hepatitin tedavisine yönelik ilaçlar olarak kullanımı.
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
UY35980A (es) 2014-02-06 2015-08-31 Janssen Sciences Ireland Uc Derivados de sulfamoilpirrolamida como inhibidores del hbv y composiciones farmacéuticas que los contienen
US20170107203A1 (en) * 2014-02-27 2017-04-20 Epirus Biopharmaceuticals, Inc. Heterocyclic inhibitors of the sodium channel
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
CR20200378A (es) 2018-03-14 2021-01-08 Janssen Sciences Ireland Unlimited Co Régimen posológico del modulador del emsalblaje de la cápside
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
EP3966205A1 (en) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115569A (en) 1971-11-19 1978-09-19 Hoechst Aktiengesellschaft Cyclic diamine derivatives
BE791501A (fr) 1971-11-19 1973-05-17 Albert Ag Chem Werke Diamines cycliques n,n'-disubstituees et leur procede de preparation
SU1074094A1 (ru) 1982-07-30 1992-04-23 Научно-исследовательский институт фармакологии АМН СССР Гидрохлорид 4-бензилпиперазида 3-метилбензофуран-2-карбоновой кислоты, обладающий психотропной активностью
JPS5936670A (ja) 1982-08-25 1984-02-28 Takeda Chem Ind Ltd ベンゾチアゾ−ル誘導体，その製造法およびそれを含有する摂食抑制剤
US4490373A (en) * 1983-05-20 1984-12-25 Usv Pharmaceutical Corporation Method of treating asthma
DE3708292A1 (de) 1987-03-14 1988-09-29 Basf Ag Gegen einwirkung von licht stabilisierte polymere sowie neue imidazol-2-carbonsaeureanilide
JPH01132579A (ja) 1987-11-19 1989-05-25 Ss Pharmaceut Co Ltd インドール誘導体
US4937246A (en) * 1987-11-25 1990-06-26 Takeda Chemical Industries, Ltd. PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof
DK733788A (da) 1988-01-14 1989-07-15 Fujisawa Pharmaceutical Co Indolylpiperidinderivater og fremgangsmaade til fremstilling deraf
GB8827189D0 (en) * 1988-11-21 1988-12-29 Fujisawa Pharmaceutical Co 2(1h)-quinolinone compounds processes for preparation thereof & pharmaceutical composition comprising same
US5563142A (en) 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
RU2099335C1 (ru) 1989-12-28 1997-12-20 Дзе Апджон Компани Диароматические соединения
HUT64320A (en) * 1990-12-14 1993-12-28 Merrell Dow Pharma Process for production antiallergic imidazole derivatives and pharmaceutical preparations containing these compounds
JPH0525131A (ja) 1991-07-17 1993-02-02 Toray Ind Inc インドール誘導体およびその医薬用途
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
DE4307883A1 (en) 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
KR950703958A (ko) 1992-10-28 1995-11-17 로렌스 티. 웰츠 Hiv 감염증을 치료하기 위한,다른 비뉴클레오사이드 역 전사효소 억제제와 혼합된 bhap 화합물의 용도(use of bhap compounds in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of hiv infection)
WO1994024105A1 (en) 1993-04-15 1994-10-27 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
FR2705095B1 (fr) 1993-05-12 1995-06-23 Adir Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
TW270114B (ja) 1993-10-22 1996-02-11 Hoffmann La Roche
US5891902A (en) 1994-01-18 1999-04-06 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
JPH09124631A (ja) 1994-02-03 1997-05-13 Shanxi Chuiyaku Kenkyuin ベンゾフラン誘導体及びそれを含む医薬組成物
EP0782989A4 (en) 1995-07-18 1999-04-21 Kyowa Hakko Kogyo Kk INDOL DERIVATIVES
JPH09124609A (ja) 1995-11-07 1997-05-13 Nissan Chem Ind Ltd ベンズイミダゾール誘導体
TW593290B (en) * 1996-05-10 2004-06-21 Janssen Pharmaceutica Nv Alkylaminobenzothiazole and -benzoxazole derivatives
JPH09325131A (ja) 1996-06-03 1997-12-16 Japan Steel & Tube Constr Co Ltd 隅肉溶接部探傷用磁化装置
DE69730837T2 (de) 1996-07-09 2005-09-29 Nikem Research S.R.L., Baranzate Di Bollate Indolderivate zur behandlung von osteoporose
IL133960A0 (en) 1997-08-15 2001-04-30 Pfizer Prod Inc 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
AU7240398A (en) 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
EP0978512A1 (en) 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
AU2001241927A1 (en) 2000-02-28 2001-09-12 Scios Inc. Inhibitors of p38-alpha kinase
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
JP2003104975A (ja) * 2001-09-28 2003-04-09 Sumitomo Pharmaceut Co Ltd 新規なベンゾチアゾール化合物

Also Published As

Publication number Publication date
IS7716A (is) 2005-02-24
US7504426B2 (en) 2009-03-17
BR0314059A (pt) 2005-07-05
EP1545532A2 (en) 2005-06-29
NZ538401A (en) 2008-03-28
ZA200502750B (en) 2006-06-28
UA79309C2 (en) 2007-06-11
RU2005106274A (ru) 2005-11-10
WO2004022060A2 (en) 2004-03-18
AU2003265886A1 (en) 2004-03-29
WO2004022060A8 (en) 2004-06-03
KR20050033662A (ko) 2005-04-12
WO2004022060A3 (en) 2004-07-08
US20040058934A1 (en) 2004-03-25
ECSP055647A (es) 2005-05-30
CA2497827A1 (en) 2004-03-18
RS20050201A (en) 2007-06-04
AR041170A1 (es) 2005-05-04
JP2006500390A (ja) 2006-01-05
PL377087A1 (pl) 2006-01-23
CN1694704A (zh) 2005-11-09
MXPA05002575A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
NO20051694L (no) Heterosykliske forbindelser
EA200400892A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
BR0213899A (pt) Aminopirimidinas e aminopiridinas
DK1513826T3 (da) Hidtil ukendte indolylpiperidinderivater som kraftige antihistamin- og antiallergimidler
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
DK1755606T4 (da) Quinazolinonderivater, der er anvendelige som vanilloid-antagonister
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
NO20062417L (no) N-tiazol-2-yl-benzamidderivater
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20052858D0 (no) Nye tricykliske forbindelser som LTD4-antagonister
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
DK0539086T3 (da) Kondenserede pyrimidinderivater og deres anvendelse som angiotensin II-antagonister
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
TR200103490T2 (tr) Antihistaminik ve antialerjik maddeler olarak indolilpiperidin türevleri
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
DE50201565D1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
ATE308541T1 (de) 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase
ATE329916T1 (de) Azaindolylpiperidinderivate als antihistaminika und antiallergika
ATE383343T1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application